Metastatic melanoma: Chemotherapy

Emilio Bajetta(Fondazione Lanza), David Khayat, Stefania Aglione(Sorbonne Université), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Olivier Rixe(University of New Mexico), Sophie Taillibert(Sorbonne Université), Chantal Bernard-Marty(Sorbonne Université), Milena Vitali(Sorbonne Université), P. Nova(Sorbonne Université), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori)
Seminars in Oncology
October 1, 2002
10.1053/sonc.2002.35238
Cited by 165

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780